Clinical Trial Update: UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination [Phase 2]

View source ↗

Summary

University of Arkansas announced the withdrawal of a Phase II trial evaluating a novel proteasome inhibitor and IMiD combination for multiple myeloma. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN